CWC
ABMD

Carolinas Wealth Consulting’s Abiomed Inc ABMD Stock Holding History

Carolinas Wealth Consulting’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-240
Closed -$59K – 1111
2022
Q3 		$59K Buy
240
+3
+1% +$810 0.01% 307
2022
Q2 		$59K Buy
237
+88
+59% +$23.7K 0.01% 307
2022
Q1 		$49K Buy
+149
New +$45.9K 0.01% 355

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Carolinas Wealth Consulting's ABMD Position: Q4 2022 in Review

Carolinas Wealth Consulting sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 240 shares — an estimated $59K sold.

Carolinas Wealth Consulting first reported a position in ABMD in Q1 2022 and held it in 3 quarters. The position peaked at $59K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Carolinas Wealth Consulting reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 240 Abiomed Inc shares in Q4 2022, an estimated $59K.
  • Carolinas Wealth Consulting first reported a position in Abiomed Inc in Q1 2022 and held it in 3 quarters.
  • Carolinas Wealth Consulting's Abiomed Inc position peaked at $59K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2022, filed 14 Feb 2023.